Eph receptors as therapeutic targets in glioblastoma

por Day, B W, Stringer, B W, Boyd, A W
Publicado 2014

Characterization of various classes of protein adducts.

por Tannenbaum, S R, Skipper, P L, Wishnok, J S, Stillwell, W G, Day, B W, Taghizadeh, K
Publicado 1993

The point mutation UCH-L1 C152A protects primary neurons against cyclopentenone prostaglandin-induced cytotoxicity: implications for post-ischemic neuronal injury

por Liu, H, Li, W, Rose, M E, Hickey, R W, Chen, J, Uechi, G T, Balasubramani, M, Day, B W, Patel, K V, Graham, S H
Publicado 2015

Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways

por Hallal, S., Mallawaaratchy, D. M., Wei, H., Ebrahimkhani, S., Stringer, B. W., Day, B. W., Boyd, A. W., Guillemin, G. J., Buckland, M. E., Kaufman, Kimberley L.
Publicado 2018

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma

por Greenall, S A, Lim, Y C, Mitchell, C B, Ensbey, K S, Stringer, B W, Wilding, A L, O'Neill, G M, McDonald, K L, Gough, D J, Day, B W, Johns, T G
Publicado 2017

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant

por Zakaria, Z, Tivnan, A, Flanagan, L, Murray, D W, Salvucci, M, Stringer, B W, Day, B W, Boyd, A W, Kögel, D, Rehm, M, O'Brien, D F, Byrne, A T, Prehn, J H M
Publicado 2016